Corporate Banner
Satellite Banner
qPCR
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

QIAGEN, AstraZeneca to Develop Liquid Biopsy-based Companion Diagnostic

Published: Monday, July 28, 2014
Last Updated: Monday, July 28, 2014
Bookmark and Share
The collaboration is to advance EGFR mutation profiling in lung cancer patients.

QIAGEN today announced a collaboration agreement with AstraZeneca PLC for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with IRESSA, AstraZeneca’s targeted therapy for non-small cell lung cancer (NSCLC). The project builds on a master framework agreement signed by both companies in 2013 and aims to develop and market a novel QIAGEN companion diagnostic that analyzes plasma samples to assess EGFR mutation status in NSCLC patients. The assay will be designed to guide the treatment of NSCLC patients with Astra Zeneca’s oral monotherapy anti-cancer treatment when tumour tissue is not available. QIAGEN already offers the therascreen EGFR RGQ PCR Kit (therascreen EGFR test) as a tissue-based companion diagnostic for lung cancer patients, which was approved in the U.S. by the FDA in July 2013 and in China in May 2014.

The companies will collaborate to create a new companion diagnostic for IRESSA based on liquid biopsy samples from NSCLC patients, rather than requiring invasive surgical collection of tissue samples. Data from several studies, including the IFUM Study (IRESSA Follow-up Measure) presented at the “World Lung 2013” conference, provided evidence of the ability to assess the EGFR status of advanced lung cancer patients using blood / plasma samples. This breakthrough provides hope for patients for whom surgical biopsy is not an option by enabling them to have their EGFR mutation status assessed using a less invasive method.

Mondher Mahjoubi, Senior Vice President, Global Product Strategy for Oncology at AstraZeneca, said: “By combining AstraZeneca’s expertise in lung cancer with QIAGEN’s diagnostic capabilities, we have the potential to transform the way specific tumour types are identified and treated. The use of circulating tumour DNA testing will allow doctors to target the individual needs of each patient quickly and accurately.”

“We are very pleased to collaborate with AstraZeneca in developing this new tool to improve life for lung cancer patients. This collaboration will further expand QIAGEN’s rapidly growing portfolio of liquid biopsy solutions for personalized healthcare which paves a path for patient monitoring using blood tests for future QIAGEN therascreen companion diagnostics. We are changing the treatment landscape with highly reliable genomic tests based on blood samples or other body fluids, providing physicians and patients with additional options to determine treatments and monitor progress,” said Peer M. Schatz, Chief Executive Officer of QIAGEN. “This new project with AstraZeneca under our master collaboration agreement, one of several such Pharma partnerships, adds to our expanding portfolio of reliable companion diagnostics which are creating valuable test content for the QIAsymphony family of automated instruments. As tests are developed, commercialization is accelerated through the established network of laboratories already using assays in QIAGEN’s industry-leading portfolio of companion diagnostics.”

IRESSA is an epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitor that acts to block signals for cancer cell growth and survival. Certain EGFR gene mutations occur in a significant number of lung cancers, and these mutation-positive tumours are particularly sensitive to IRESSA. QIAGEN and AstraZeneca plan to develop a test that detects 21 EGFR mutations to identify patients most likely to benefit from the therapy, adapting QIAGEN technologies from the FDA-approved therascreen® EGFR RGQ PCR Kit. The new test kit is planned to run on QIAGEN's Rotor-Gene Q system, a member of the QIAsymphony family of automated instruments.

QIAGEN is at the forefront in developing and validating companion diagnostics to guide the selection of medicines in treating cancer and other diseases. In the United States, QIAGEN received FDA approvals in 2012 and 2014 for the therascreen® KRAS RGQ PCR Kit in colorectal cancer and in 2013 for the therascreen EGFR test in NSCLC. Last month, QIAGEN announced a collaboration with Lilly to develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers. Earlier this year, QIAGEN entered into a collaboration with Exosome Diagnostics to develop first-in-class, non-invasive diagnostics for key genetic biomarkers in lung and other cancers. QIAGEN’s leading portfolio of liquid biopsy technologies also includes the QIAamp Circulating Nucleic Acid Kit, which is considered to be the gold standard sample technology for the processing of free circulating DNA and RNA, as well as the REPLI-g product line, which enables genomic analysis from single cells.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Qiagen Bids $100M to Acquire Exiqon
Transaction will expand leadership position in RNA technologies.
Thursday, March 31, 2016
QIAGEN Signs Ninth Master Collaboration Agreement for Companion Diagnostics
Master collaboration agreement is a framework for developing and commercializing QIAGEN companion diagnostics, paired with new or existing products.
Thursday, November 13, 2014
QIAGEN Receives FDA Approval for CMV Assay
Assay offers faster quantification of CMV DNA levels in patient samples.
Friday, June 20, 2014
QIAGEN, Lilly form CDx Collaboration
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.
Friday, May 30, 2014
FDA Approve QIAGEN PCR Kit For Use With Second Colorectal Cancer Drug
Clinically proven companion diagnostic gains U.S. approval to guide use of Amgen’s Vectibix® (panitumumab) in treatment of metastatic colorectal cancer.
Tuesday, May 27, 2014
QIAGEN Receives FDA Clearance for QIAsymphony RGQ MDx
Clearance marks a milestone for one of the Company’s major global growth drivers.
Monday, May 05, 2014
QIAGEN Licences Biomarker for Blood Disorder from CeMM Vienna
Company plans to develop a molecular diagnostic test for the calreticulin mutations.
Thursday, April 10, 2014
QIAGEN Partners with Exosome Diagnostics
Molecular testing of biofluids promises unprecedented access to gene mutations, gene expression signatures and expression levels without costly, invasive tissue biopsies.
Wednesday, July 24, 2013
QIAGEN Acquires Ingenuity Systems
Suite of web-based applications powered by a unique expert-curated Knowledge Base eases major bottlenecks to leveraging genomic data in research and clinical diagnostics.
Thursday, May 02, 2013
QIAGEN’s KRAS Companion Diagnostic for Colorectal Cancer Adopted by Clarient
Clarient offers network of 2,000-plus pathologists testing with therascreen KRAS RGQ PCR Kit, the companion diagnostic for Erbitux® in metastatic colorectal cancer.
Wednesday, January 30, 2013
QIAGEN Submits Companion Diagnostic to FDA
Companion diagnostic intended to aid treatment decisions in non-small cell lung cancer.
Tuesday, January 22, 2013
QIAGEN Adds to Pipeline of Personalized Healthcare Diagnostics
Includes investment in new companion diagnostic that aims to predict efficacy of TNF-alpha inhibitors in rheumatoid arthritis patients.
Tuesday, January 08, 2013
QIAGEN Achieves Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
U.S. launch of therascreen® KRAS RGQ PCR kit offers enhanced approach to guide treatments for approximately 110,000 patients annually in U.S. with colorectal cancer.
Wednesday, July 11, 2012
QIAGEN Unveils Initiative to Create Next-generation Sequencing Portfolio
Company plans to offer sample-to-result workflows that integrate its sample preparation and assay products with a next-generation benchtop sequencer and new bioinformatics.
Tuesday, June 26, 2012
QIAGEN Receives FDA Clearances for Rotor-Gene Q MDx Instrument and Compatible Influenza A/B Assay
Both products receive 510(k) clearance for in vitro diagnostic use in the U.S..
Tuesday, April 17, 2012
Scientific News
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Gene Analysis System Could Accelerate Pace of Research on the Space Station
The WetLab-2 system will enable spaceflight genomic studies involving a wide variety of biospecimen types in the unique microgravity environment of space.
Liquid Biopsy for NSCLC
'Liquid biopsy' blood test accurately detects key genetic mutations in most common form of lung cancer, study finds.
Rare DNA Will Have Nowhere To Hide
Two National Institutes of Health grants back Rice University effort to develop new diagnostics.
Seeing Cell to Cell Differences
Seeing differences between individual cells for first time explains symptoms of rare genetic disorders, finds penn study.
Circular RNAs Implicated in Cancer
Circular RNAs – like their protein counterparts – are also affected by genomic rearrangements in cancer, resulting in abnormal fusions.
Know Thy Helicobacter pylori
Non-invasive method for genotyping H.pylori developed.
Zika Test Authorized for Emergency Use
n response to a request from the CDC, the FDA has issued an Emergency Use Authorization (EUA) for a diagnostic tool for Zika virus that will be distributed to qualified laboratories.
Lighting Up Disease-Carrying Mosquitoes
Sandia’s QUASR enables speedy, accurate detection of West Nile and other viruses.
Ultra-Sensitive Test for Cancers, HIV
Test developed that is thousands of times more sensitive than current diagnostics.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!